

January 7, 2022

To
BSE Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai - 400 001

To
The National Stock Exchange of India Ltd
Exchange Plaza,
Bandra Kurla Complex, Bandra (E)
Mumbai - 400 001

Scrip Code: 524558

Scrip Code: NEULANLAB; Series: EQ

Dear Sirs,



Sub: Notice of Board Meeting

Pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that a meeting of Board of Directors of the Company is scheduled to be held on Tuesday, February 1, 2022, inter-alia, to approve and take on record the unaudited financial results (standalone and consolidated) of the Company for the quarter and nine months ended December 31, 2021.

In continuation to our letter dated December 27, 2021, as per the provisions of the Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information of the Company, the trading window for dealing in the securities of the Company for Designated Persons, their immediate relatives and other Insiders, covered in terms of the Company's Code of Conduct under SEBI (Prohibition of Insider Trading), Regulations, 2015, which was closed from January 1, 2022, shall open after forty-eight hours of declaration of unaudited financial results of the Company for the quarter and nine months ended December 31, 2021, to the Stock Exchanges.

This is for your information and records.

Thanking you,
Yours faithfully,
For **Neuland Laboratories Limited**



Sarada Bhamidipati
Company Secretary
M. No. 27854